Application of anti-inflammatory enhanced mitochondria in preparation of medicine for treating sepsis

The anti-inflammatory enhanced mitochondria prepared by combining exogenous cell membranes with exogenous mitochondria has solved the problem of insufficient inflammation regulation ability in acute lung injury in sepsis, significantly improved lung function and inflammation level, and improved treatment effect.

CN119055682APending Publication Date: 2024-12-03CHONGQING QUANSHENG PHARM TECH CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411064402.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art lacks effective inflammatory control strategies in treating acute lung injury in sepsis. Although mitochondrial transplantation can repair cell damage, it lacks efficient inflammatory control capabilities and makes it difficult to improve the therapeutic effect.

Method used

Anti-inflammatory enhanced mitochondria are used to prepare drugs for the treatment of sepsis by combining the exogenous cell membrane with the exogenous mitochondria, which has the effect of adsorbing inflammatory factors, regulating inflammation levels and repairing cell damage.

Benefits of technology

In in vitro experiments and mouse models, anti-inflammatory enhanced mitochondria significantly improved lung tissue function, lung mitochondria function and in vivo inflammation, reduced inflammatory cell recruitment and inflammatory factors, and improved therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055682A_ABST
    Figure CN119055682A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and discloses an application of anti-inflammatory enhanced mitochondria in preparation of a medicine for treating sepsis, and the anti-inflammatory enhanced mitochondria is combined from an exogenous cell membrane to an outer membrane of an exogenous mitochondria. In-vitro experiments prove that the anti-inflammatory enhanced mitochondria provided by the invention has the effects of adsorbing inflammatory factors, regulating the inflammation level and repairing cell injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to the application of anti-inflammatory enhanced mitochondria in the preparation of drugs for treating sepsis. Background Art

[0002] Sepsis is a systemic inflammatory response syndrome caused by infection, among which acute lung injury caused by endotoxin is a common cause of death in sepsis. The mechanism of acute lung injury in sepsis is mainly inflammatory response and cell damage. At present, the treatment of acute lung injury in sepsis usually uses conservative treatments such as antibiotics and mechanical ventilation, and there is no better treatment strategy yet. Mitochondrial transplantation, as an emerging treatment strategy for cell damage, has shown good therapeutic effects in injury models. Compared with traditional small molecule drugs, supplementing damaged cells with healthy mitochondria can quickly repair mitochondrial damage and restore cell function. However, mitochondria lack efficient inflammation regulation ability. How to give them inflammation regulation ability and improve the therapeutic effect of mitochondrial transplantation in sepsis acute lung injury is a key problem that needs to be solved at present. Summary of the invention

[0003] The present invention provides an application of an anti-inflammatory enhanced mitochondria in the preparation of a drug for treating sepsis. The anti-inflammatory enhanced mitochondria is an outer membrane of an exogenous cell membrane bound to an exogenous mitochondria.

[0004] According to some embodiments, the present invention is used to prepare a medicament for treating sepsis and related complications.

[0005] According to some embodiments, the sepsis complication comprises at least one of septic shock, acute lung injury, acute respiratory distress syndrome.

[0006] According to some embodiments, the anti-inflammatory enhanced mitochondria include at least one of features (A1) to (A2): (A1) the exogenous cell membrane is extracted from at least one of neutrophils, monocytes, lymphocytes, and tumor cells; (A2) the exogenous mitochondria are separated from cells or body tissues, and the body tissues include at least one of myocardial tissue, liver tissue, brain tissue, muscle tissue, blood, and tissue fluid; its specific preparation method is the same as CN113122497A.

[0007] According to some embodiments, the drug has at least one of the following effects (B1) to (B8): (B1) reduction in alveolar septum; (B2) decrease in the number of inflammatory cells; (B3) reduction in serum inflammatory factors, including at least one of TNF-α, IL-6, and IL-1β; (B4) reduction in liver function index values ​​and kidney function index values; (B5) increase in PaCO2 levels; (B6) reduction in neutrophil recruitment and inhibition of inflammatory infiltration of lung tissue; (B7) increase in the expression levels of ZO-1 and HO-1 proteins; and (B8) decrease in reactive oxygen species content.

[0008] According to some embodiments, the drug includes an active ingredient and a pharmaceutically acceptable excipient, and the active ingredient is an anti-inflammatory enhanced mitochondria.

[0009] According to some embodiments, the pharmaceutically acceptable excipients include at least one of solvents, propellants, solubilizers, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants.

[0010] According to some embodiments, the dosage form of the drug includes at least one of oral solution, powder, tablet, capsule, granule, decoction, pill, spray, inhalant, atomizer and injection.

[0011] According to some embodiments, the drug is used in combination with other anti-tumor drugs.

[0012] The beneficial effects achieved by the present invention are:

[0013] The present invention constructs enhanced mitochondria with inflammation regulation; the anti-inflammatory enhanced mitochondria provided by the present invention have been verified in in vitro experiments to have three major functions: adsorbing inflammatory factors, regulating inflammation levels, and repairing cell damage; the anti-inflammatory enhanced mitochondria provided by the present invention have the functions of improving mouse lung tissue function, lung mitochondrial function, and regulating inflammation levels in the body in mice with acute lung injury caused by sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 Results of the measurement for establishing a sepsis-induced acute lung injury model: (A) lung mitochondrial JC-1 content; (B) lung ROS production; (C) blood carbon dioxide partial pressure; (D) lung dry and wet weight; (E) lung HE staining; Figure 2Results of serum index tests for sepsis: (A) serum AST level; (B) serum ALT level; (C) serum BUN level; (D) serum CRE level; (E) serum inflammatory factor TNF-α level; (F) serum inflammatory factor IL-6 level; Figure 3 Results of the evaluation of the therapeutic effects of different concentrations of anti-inflammatory enhanced mitochondria: (A) lung dry and wet weight levels; (B) lung mitochondrial membrane potential levels; (C) lung HE staining; Figure 4 Results of the evaluation of the therapeutic effects of different concentrations of anti-inflammatory enhanced mitochondria: (A) serum inflammatory factor TNF-α level; (B) serum inflammatory factor IL-6 level; (C) serum inflammatory factor IL-1β level; Figure 5 Results of the evaluation of the therapeutic effects of different concentrations of anti-inflammatory enhanced mitochondria: (A) serum ALT level; (B) serum AST level; (C) serum BUN level; (D) serum CRE level; Figure 6 It is the result of blood carbon dioxide partial pressure measurement; Figure 7 The results of lung dry and wet weight after anti-inflammatory enhanced mitochondrial treatment; Figure 8 The results show the effect of anti-inflammatory enhanced mitochondria on mitochondrial function in lung tissue: (A) ROS production in lung tissue; (B) mitochondrial membrane potential level in lung tissue; Fig. 9 The results of the regulation of serum inflammatory levels of mice by anti-inflammatory enhanced mitochondria: (A) serum inflammatory factor TNF-α level; (B) serum inflammatory factor IL-1β level; (C) serum inflammatory factor IL-6 level; Fig.10 Results of lung pathological staining: (A) lung HE staining; (B) lung HE result score; Fig.11 Results of lung tissue inflammation: (A) lung immunohistochemical IL-1β staining; (B) lung immunohistochemical IL-6 staining; (C) serum inflammatory factor TNF-α staining; Fig.12 Results for MPO levels in lung tissue; Fig.13 To construct the RAW264.7 cell inflammatory model, the results are as follows: (A) NO concentration in the cell supernatant; (B) IL-6 level in the cell supernatant; (C) TNF-α level in the cell supernatant; Fig.14 The results of the regulation of inflammatory factor levels in RAW264.7 cells by anti-inflammatory enhanced mitochondria: (A) NO level in cell supernatant; (B) IL-6 level in cell supernatant; (C) TNF-α level in cell supernatant; Fig.15 Evaluation results of anti-inflammatory enhanced mitochondria adsorption of inflammatory factors: (A) inflammatory factor IL-1β level; (B) inflammatory factor IL-6 level; (C) inflammatory factor TNF-α level; Fig.16Evaluation results of the anti-inflammatory enhanced mitochondria on the damage and repair of Beas-2B cells: (A) mitochondrial ATP level in Beas-2B cells; (B) ROS level in Beas-2B cells; Fig.17 Evaluation results of the functional restoration of Beas-2B cells by anti-inflammatory enhanced mitochondria: (A) ICAM-1 immunofluorescence results; (B) ICAM-1 protein semi-quantification; Fig.18 Evaluation results of the functional repair of Beas-2B cells by anti-inflammatory enhanced mitochondria: (A) HO-1 expression in Beas-2B cells; (B) HO-1 protein semi-quantification; (C) ZO-1 expression in Beas-2B cells; (D) ZO-1 protein semi-quantification; Fig.19 To construct the Beas-2B cell injury model, the results were as follows: (A) mitochondrial ATP level in Beas-2B cells; (B) mitochondrial ROS level in Beas-2B cells; Fig. 20 To construct the Beas-2B cell injury model results: (A) Mitochondrial membrane potential of Beas-2B cells; (B) Figure (A) Semi-quantification of mitochondrial membrane potential; Fig.21 Evaluation results of mitochondrial function restoration in Beas-2B cells: (A) Mitochondrial membrane potential of Beas-2B cells; (B) Semi-quantitative analysis of mitochondrial membrane potential of Beas-2B cells in Figure (A); Fig. 22 Evaluation results of mitochondrial function repair in Beas-2B cells: (A) ATP in Beas-2B cells; (B) ROS in Beas-2B cells; Fig.23 Evaluation results of Beas-2B cell function recovery: (A) AAT content of Beas-2B cells; (B) ZO-1 expression of Beas-2B cells; (C) semi-quantification of ZO-1 protein; (D) HO-1 expression of Beas-2B cells; (E) semi-quantification of HO-1 protein. DETAILED DESCRIPTION

[0015] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0016] Example 1

[0017] 1. Mitochondria Extraction

[0018] (1) Select 5-8 week old male C57 mice, disinfect with 75% alcohol, quickly remove the heart, put it in pre-cooled PBS, wash 5 times, quickly pump out the residual blood in the heart, cut it into pieces, and place it in an ice bath for 3 minutes. (2) Centrifuge at 4℃, 600g for 20 seconds, and discard PBS. (3) Add an appropriate amount of pancreatic enzyme digestion solution and digest it in an ice bath for 20 minutes. (4) Centrifuge at 4℃, 600g for 20 seconds, and discard pancreatic enzyme. (5) Add an appropriate amount of mitochondrial isolation reagent to wash away residual pancreatic enzyme. (6) Add an appropriate amount of mitochondrial isolation reagent again, and homogenize it in an ice bath for 20-30 times. (7) Centrifuge the homogenate suspension at 4℃, 1000g for 5 minutes. (8) Aspirate the supernatant, centrifuge at 4℃, 3500g for 10 minutes, and the precipitate is the mitochondria.

[0019] 2. Extraction of Neutrophil Membranes

[0020] (1) After the mice were anesthetized with ether, they were killed by cervical dislocation. The tibia and femur of the mice were quickly separated and the excess muscle tissue was removed. (2) The separated tibia and femur were immersed in a small glass dish filled with RPIM 1640 complete culture medium. (3) All tissues around the bones were removed with microtweezers, and the joints at both ends of the bones were cut to expose the bone marrow cavity. (4) The bone marrow cavity of the tibia and femur was rinsed with culture medium. (5) After obtaining the bone marrow suspension, neutrophils were separated by density gradient centrifugation. (6) Neutrophils were activated with an appropriate concentration of LPS. (7) An appropriate amount of separation buffer containing PMSF was added, and the cells were broken by ultrasound for 5 minutes. (8) Neutrophil membranes were obtained by centrifugation at 4°C and 10,000 g for 10 minutes.

[0021] 3. Preparation of Anti-Inflammatory Enhanced Mitochondria

[0022] (1) The extracted mitochondria and neutrophil membranes were fused at a certain mass ratio and ultrasonically fused in an ice water bath for 3 minutes. (2) After the ultrasonication, centrifuge at 4°C, 3500g for 10 minutes. (3) The precipitate was washed twice with PBS to obtain anti-inflammatory enhanced mitochondria.

[0023] In vivo experiments

[0024] 1. Establishment of Sepsis-induced Acute Lung Injury Model

[0025] The mice were divided into a Healthy group and a Model group. The Model group was intraperitoneally injected with 15 mg / kg LPS for 4 hours, and the Healthy group was injected with an equal amount of normal saline. After the modeling was completed, whole orbital blood was collected, left to stand at room temperature for 2 hours, and centrifuged at 4°C, 4000r for 15 minutes to collect serum. The collected serum was used to detect inflammatory factors TNF-α and IL-6, liver function ALT and AST, and renal function creatinine and urea nitrogen. After the mice were killed by dislocation, the mouse lung tissues were collected, one part was used for lung dry and wet weight determination, one part was used for lung mitochondrial function ATP, ROS, and JC-1 determination, and one part was used for 4% paraformaldehyde fixation for pathological staining.

[0026] The experimental results are as follows Figure 1 As shown, the mitochondrial function JC-1 and ROS of lung tissue were detected. It was found that compared with the Healthy group, the mitochondrial membrane potential of the Model group decreased (P < 0.05), and the ROS production increased significantly (P < 0.01), indicating that the mitochondrial function of lung tissue was damaged. Analysis of the results of pulmonary blood gas detection showed that after LPS modeling, the partial pressure of carbon dioxide decreased, indicating that lung function may be damaged. In order to further evaluate the changes in lung tissue function, the changes in lung dry-wet ratio after modeling were then detected, and it was found that the lung dry-wet weight ratio of the Model group increased significantly (P < 0.05). In addition, the results of lung tissue HE staining showed that the alveolar cavity in some parts of the Model group was enlarged and fused, the alveolar septum was thickened, and there was obvious inflammatory cell infiltration around the bronchi, mainly neutrophils.

[0027] Sepsis is a systemic inflammatory response syndrome that can cause tissue damage, organ failure, and death during its occurrence and development. Therefore, we evaluated the changes in serum inflammation levels and liver and kidney function in mice after modeling. Figure 2 It can be seen that the levels of AST, ALT, BUN, and CRE in the model group increased significantly (P < 0.05). Elisa was used to detect serum inflammatory factors TNF-α and IL-6, and the results showed that the inflammatory factors in the model group were all upregulated (P < 0.05). The above experimental results confirmed that we can construct a sepsis acute lung injury model by intraperitoneal injection of 15mg / Kg LPS.

[0028] 2. Screening of anti-inflammatory enhancing mitochondrial administration concentrations

[0029] All mice were randomly divided into 5 groups: ① Healthy group: equal amount of normal saline, ② Model group (15mg / kgLPS), ③ low-dose treatment group (0.5mg / kg NEM-MITO), ④ medium-dose treatment group (1mg / kg NEM-MITO), ⑤ high-dose treatment group (2mg / kg NEM-MITO). LPS was injected intraperitoneally to construct the model, and the Healthy group was injected with normal saline. Four hours after modeling, fresh mitochondria were extracted, and anti-inflammatory enhanced mitochondria were prepared as therapeutic drugs. The treatment group was given different doses of anti-inflammatory enhanced mitochondria by tail vein injection, and the Healthy group and Model group were given the same amount of normal saline at the same time, and the treatment was administered for 20 hours. After the end of the administration, orbital venous blood and heart, liver, spleen, lung and kidney tissues were collected. Serum was collected by centrifugation to detect inflammatory factors TNF-α, IL-6, IL-1β, liver function indicators such as ALT and AST, heart, liver, spleen, lung and kidney were collected, weighed and photographed to evaluate the index of each organ, fresh lung tissue was collected to detect lung dry and wet weights and lung mitochondrial function ATP, ROS, JC-1, and the heart, liver, spleen, lung and kidney were also fixed with 4% paraformaldehyde for pathological staining.

[0030] The changes in lung function were evaluated by testing lung dry and wet weight, lung tissue mitochondrial JC-1 and lung pathological staining. The experimental results are as follows Figure 3 As shown. 1mg / Kg and 2mg / Kg of anti-inflammatory enhanced mitochondria can reduce the lung dry-wet weight ratio, while 0.5mg / Kg, 1mg / Kg, and 2mg / Kg of anti-inflammatory enhanced mitochondria can improve mitochondrial membrane potential, among which 1mg / Kg of anti-inflammatory enhanced mitochondria has a more obvious improvement effect (P < 0.001). HE staining results are shown in Figure 3 As shown in (C), after treatment with different concentrations of anti-inflammatory enhanced mitochondria, the alveolar septa decreased and the number of inflammatory cells also decreased.

[0031] In order to verify the effects of different concentrations of anti-inflammatory enhanced mitochondria on serum inflammatory factors and liver and kidney function of mice after LPS modeling, we then detected serum inflammatory factors TNF-α, IL-6, and IL-1β, and found that 0.5 mg / Kg, 1 mg / Kg, and 2 mg / Kg of anti-inflammatory enhanced mitochondria could reduce serum inflammatory factors (P < 0.01), but when comparing the degree of reduction of the three treatment concentrations, it was found that 1 mg / Kg had a greater decrease.

[0032] In addition, we also tested the changes in serum liver function ALT, AST and kidney function BUN and CRE, and found that compared with the model group, the three treatment concentrations of 0.5mg / Kg, 1mg / Kg and 2mg / Kg could reduce the liver and kidney function levels. However, considering their ability to regulate liver and kidney function, we found that 1mg / Kg of anti-inflammatory enhanced mitochondria had the best effect.

[0033] In summary, we tested the lung dry-to-wet weight ratio, lung mitochondrial function JC-1, lung HE staining, as well as serum inflammatory factors and liver and kidney function indicators. We found that the three treatment concentrations of 0.5 mg / Kg, 1 mg / Kg, and 2 mg / Kg all had certain therapeutic effects. However, in order to compare the optimal treatment concentration for the therapeutic effect and consider the economic benefits, we used 1 mg / Kg as the optimal treatment concentration.

[0034] 3. In vivo evaluation of anti-inflammatory enhanced mitochondria in the treatment of acute lung injury in sepsis

[0035] In order to evaluate the effect of anti-inflammatory enhanced mitochondria on blood gas changes in mice with acute lung injury caused by sepsis, we divided the experiment into four groups: ① Healthy control group (Healthy), ② Model group (Model), ③ Normal mitochondria treatment group (MITO), ④ Anti-inflammatory enhanced mitochondria treatment group (NEM-MITO). After LPS modeling, the treatment groups were treated with normal mitochondria and anti-inflammatory enhanced mitochondria, respectively, and then blood gas analysis was performed. The results are shown in the figure. Figure 6 As shown, we found that the blood carbon dioxide partial pressure (PaCO2) in the model group was the lowest among the four groups, and after treatment, its PaCO2 level recovered to a certain extent (P < 0.01), indicating that anti-inflammatory enhanced mitochondria can restore the lung function of mice.

[0036] In order to evaluate the improvement of pulmonary edema in mice, we used the lung dry-to-wet weight ratio of mice. Figure 7 As shown in the figure, after LPS modeling and administration, the degree of pulmonary edema was found to be greater, while after anti-inflammatory enhanced mitochondrial treatment, the lung dry-to-wet weight ratio decreased (P < 0.05), indicating that pulmonary edema was improved to a certain extent.

[0037] To verify whether mitochondrial supplementation can improve mitochondrial function, we detected changes in lung mitochondrial function after treatment. Figure 8 As shown in the results, it was found that both common mitochondria and anti-inflammatory enhanced mitochondria could restore mitochondrial function ROS and JC-1 to a certain extent, but the recovery ability of anti-inflammatory enhanced mitochondria was more significant (P < 0.05). We observed that after anti-inflammatory enhanced mitochondria treatment, mitochondrial function ROS and JC-1 were restored to a certain extent. We speculate that it may be that the anti-inflammatory enhanced mitochondria contain neutrophil membranes and have the ability to target the damaged site, so they can significantly improve the mitochondrial function of damaged lungs.

[0038] The changes in inflammatory factors in mouse serum are key detection indicators for sepsis treatment. By detecting serum inflammatory factors, we can observe the changes in systemic inflammation. Using Elisa to detect the changes in serum inflammatory factors TNF-α, IL-1β, and IL-6, it was found that the expression of inflammatory factors in the model group of each indicator was the highest, indicating that LPS can cause systemic inflammation. After treatment with ordinary mitochondria and anti-inflammatory enhanced mitochondria, the levels of inflammatory factors were downregulated. We observed the downward trend and found that the downward trend of anti-inflammatory enhanced mitochondria was more obvious (P < 0.05).

[0039] HE staining was performed on paraffin sections to evaluate the damage of lung tissue. Fig.10 As shown in (A), compared with the Healthy group, the alveolar wall in the Model group was thickened, the alveolar structure was destroyed, a large number of inflammatory cells infiltrated, and there was bleeding. The degree of lung injury in the MITO group after mitochondrial treatment and the NEM-MITO group after anti-inflammatory enhanced mitochondrial treatment was significantly reduced. Among them, the recovery of lung injury in the NEM-MITO group was better than that in the MITO group. In addition, we scored the degree of lung tissue injury, and the scoring results are shown in the figure below. Fig.10 As shown in (B), the injury score of the model group was the highest, which was consistent with the HE staining results we observed.

[0040] IL-1β, IL-6, and TNF-α are common inflammatory mediators in LPS-induced inflammatory responses. They can not only directly damage lung cells, but also stimulate other immune cells to secrete inflammatory mediators, thereby further damaging lung cells and promoting the development of lung injury. We have previously verified that anti-inflammatory enhanced mitochondria can reduce the levels of inflammatory factors IL-1β, IL-6, and TNF-α in serum. We will further verify the ability of anti-inflammatory enhanced mitochondria to regulate inflammation in lung tissue through immunohistochemistry. The experimental results are as follows Fig.11 As shown, we found that the Model group had the most brown precipitates, while after NEM-MITO treatment, the brown precipitates were significantly reduced. Therefore, we determined that anti-inflammatory enhanced mitochondria can reduce inflammatory factors in lung tissue.

[0041] We evaluated the infiltration of neutrophils by evaluating MPO activity. Fig.12 As shown, compared with the Healthy group, the Model group had the highest MPO expression, while the MPO level in the lung tissue treated with NEM-MITO was significantly downregulated. From this, we infer that NEM-MITO can reduce the recruitment of neutrophils and thus the inflammatory infiltration of lung tissue.

[0042] In vitro experiments

[0043] 1. Construction of RAW264.7 cell inflammation model

[0044] When RAW264.7 cells reached the logarithmic phase, the cells were cultured at 4×10 4 (cells / well) were inoculated in a 12-well plate. After 12 hours of attachment, the cells were washed twice with 1 mL PBS and replaced with serum-free medium containing 1 μg / mL LPS. After 12 hours of continued culture, the supernatant of the culture medium was collected. Centrifuged at 4°C, 17,000 r for 20 minutes to remove cell impurities, and the supernatant was collected to detect NO, inflammatory factors IL-6, and TNF-α levels.

[0045] Experimental Example 2 Regulation of the inflammatory level of RAW264.7 cells by anti-inflammatory enhanced type

[0046] To evaluate the ability of anti-inflammatory enhanced mitochondria to regulate inflammation in RAW264.7 cells, this part of the experiment was divided into Control group, Model group, MITO group, and NEM-MITO group. After the cells were plated and reached the appropriate density, 1 μg / mL LPS was added to the Model group, MITO group, and NEM-MITO group for 24 hours. After the modeling was completed, the drug-containing culture medium of 25 μg / mL mitochondria and anti-inflammatory enhanced mitochondria was replaced and cultured for another 24 hours. After the treatment, the cell supernatant was taken to detect the levels of NO, TNF-α, and IL-6. After the administration of mitochondria and anti-inflammatory enhanced mitochondria, the nitric oxide levels of both groups decreased significantly compared with the Model group (P < 0.01). However, compared with mitochondria, the downward trend of anti-inflammatory enhanced mitochondria was more obvious (P < 0.05). At the same time, the levels of inflammatory factors TNF-α and IL-6 in the cell supernatant were also detected. Compared with the Model group, the levels of inflammatory factors were improved to a certain extent after the administration of mitochondria and anti-inflammatory enhanced mitochondria. Moreover, by comparing the decreasing trend of inflammatory factor TNF-α, we found that the decreasing trend of anti-inflammatory enhanced mitochondria group was more obvious than that of mitochondria. In summary, we verified that anti-inflammatory enhanced mitochondria can regulate the levels of nitric oxide and inflammatory factors in RAW264.7 cells after LPS stimulation.

[0047] 3. Study on the adsorption of inflammatory factors by anti-inflammatory enhanced mitochondria

[0048] To investigate the inflammatory factor adsorption capacity of anti-inflammatory enhanced mitochondria. After stimulating RAW264.7 cells with LPS for 24 hours, the cell supernatant was collected. Ordinary mitochondria and anti-inflammatory enhanced mitochondria were added to the collected cell supernatant and incubated in a 37°C cell culture incubator for 4 hours, followed by centrifugation at 4°C, 16000g for 20 minutes to remove ordinary mitochondria and anti-inflammatory enhanced mitochondria. The concentrations of inflammatory factors IL-1β, IL-6, and TNF-α in the culture medium supernatant were determined by enzyme-linked immunosorbent assay. The experimental results are as follows. Fig.15 As shown, the adsorption capacity of anti-inflammatory enhanced mitochondria to inflammatory factors was stronger than that of ordinary mitochondria (P < 0.05), and the results of this adsorption capacity were consistent in the three indicators of IL-1β, IL-6, and TNF-α.

[0049] In order to confirm whether the cell supernatant after adsorption of ordinary mitochondria and anti-inflammatory enhanced mitochondria can reduce the effect on the mitochondrial function of Beas-2B cells, we detected the mitochondrial function ATP and ROS of Beas-2B cells. The experiment was divided into Control group, Model group, MITO group, and NEM-MITO group; the Control group added the supernatant of RAW264.7 cells without LPS stimulation, the Model group added the supernatant of RAW264.7 cells stimulated with LPS, the MITO group added the supernatant of RAW264.7 cells stimulated with LPS and adsorbed by ordinary mitochondria, and the NEM-MITO group added the supernatant of RAW264.7 cells stimulated with LPS and adsorbed by anti-inflammatory enhanced mitochondria. The cells were co-cultured in a cell culture incubator at 37°C for 24 hours. The cells were collected to detect the mitochondrial ATP of each group of cells. The experimental results are shown as follows. Fig.16 As shown, we found that the mitochondrial ATP level of the Model group adsorbed with anti-inflammatory enhanced mitochondria was the lowest, while the ATP levels of the common mitochondria group (P < 0.05) and the anti-inflammatory enhanced mitochondria group (P < 0.01) increased, and the ATP production of the anti-inflammatory enhanced mitochondria group was higher than that of the common mitochondria group (P < 0.05). The above results show that the cell damage ability of the supernatant of RAW264.7 cells after mitochondrial adsorption has decreased. Similarly, the ROS production of the Model group is the highest among the four groups. The supernatant of RAW264.7 cells adsorbed with common mitochondria and anti-inflammatory enhanced mitochondria can significantly reduce the release of ROS in Beas-2B cells (P < 0.05), and the inhibitory ability of the anti-inflammatory enhanced mitochondria group is stronger (P < 0.01).

[0050] ICAM-1 is an important intercellular adhesion molecule that can mediate cell-to-cell adhesion. We use its level to evaluate changes in Beas-2B cell function, such as Fig.17 As shown in (A), we used red fluorescent secondary antibody to mark the ICAM-1 expression of cells. It can be clearly observed that the Model group is stronger than the Control group, MITO group, and NEM-MITO group. Then ImageJ was used to semi-quantitate the collected fluorescent images. The results are shown in Fig.17 As shown in (B), the statistical results are consistent with the observed results.

[0051] In order to further verify the ability of anti-inflammatory enhanced mitochondria to adsorb inflammatory factors, we used WB to detect the expression of tight junction protein 1 (ZO-1) and heme oxygenase 1 (HO-1) of Beas-2B to evaluate the function of Beas-2B cells. ZO-1 is a tight junction protein under the cell membrane, which can characterize whether its alveolar epithelial barrier is damaged. After HO-1 is activated, it can play an anti-inflammatory and antioxidant role, thereby reducing lung damage and pulmonary edema, and improving the gas exchange function of the lungs. Similarly, ordinary mitochondria and anti-inflammatory enhanced mitochondria were used to adsorb the supernatant of RAW264.7 cells stimulated with LPS. The adsorbed cell supernatant was co-incubated with Beas-2B. After the incubation, the whole protein of Beas-2B cells was extracted, and the expression of HO-1 protein and ZO-1 protein was detected by immunoblotting. The expression of the two proteins was semi-quantitatively analyzed by Image J. The results are shown in the figure. Fig.18 As shown, the expression level in the Model group was the lowest. Compared with the Model group, the protein expression in the common mitochondria group and the anti-inflammatory enhanced mitochondria group was increased, among which the increase in the NEM-MITO group was more obvious (P < 0.01).

[0052] 4. Construction of Beas-2B cell injury model

[0053] When the cells grew to the logarithmic phase, RAW264.7 cells were taken at 4×10 4 (cells / well) were inoculated in a 12-well plate. After 12 hours of attachment, the cells were washed twice with 1 mL PBS and replaced with serum-free medium containing 1 μg / mL LPS. After culturing for another 12 hours, the supernatant of the culture medium was collected for later use. When Beas-2B cells grew to the logarithmic phase, the cells were cultured at 4×10 4 (cells / well) were inoculated in a 12-well plate. After 12 hours of attachment, the cells were washed twice with 1 mL PBS and the above-collected RAW264.7 cell culture medium was collected. After 24 hours of continuous culture, the cells were washed twice with 1 mL PBS and the cells were collected to detect the mitochondrial function ATP, ROS, and membrane potential levels of Beas-2B cells. The results are shown in Fig.18 , 19 As shown, the mitochondrial ATP and membrane potential levels of Beas-2B cells decreased and the ROS level increased after injury.

[0054] 5. Evaluation of anti-inflammatory enhanced mitochondria on the repair of mitochondrial function in Beas-2B cells

[0055] In order to verify whether supplementing mitochondria or anti-inflammatory enhanced mitochondria can repair cell damage, we constructed a Beas-2B cell injury model and observed the repair of mitochondrial function by supplementing mitochondria or anti-inflammatory enhanced mitochondria. This part of the experiment was divided into 4 groups: Control group, Model group, MITO group, and NEM-MITO group. RAW264.7 cells were treated with 1μg / mL LPS for 24 hours. After the stimulation, the supernatant of RAW264.7 cells was taken and added to the Model group, MITO group, and NEM-MITO group for incubation for 24 hours. The Control group continued to be cultured with an equal amount of culture medium. After the incubation was completed, fresh mitochondria were extracted and anti-inflammatory enhanced mitochondria were prepared. The culture medium of the MITO group was replaced with 25μg / mL mitochondria, the culture medium of the NEM-MITO group was replaced with 25μg / mL anti-inflammatory enhanced mitochondria, and the control group and model group were replaced with an equal amount of complete culture medium. After the addition of drugs and incubation, the culture medium in the well plate was discarded, the cells were washed twice with PBS, and the cells were collected after washing to detect mitochondrial ATP, mitochondrial ROS, and mitochondrial membrane potential. First, the effect of anti-inflammatory enhanced mitochondria on the mitochondrial membrane potential of Beas-2B cells was detected, and the JC-1 staining results were collected using a fluorescence microscope. Fig. 20 It can be seen that after treatment with mitochondria or anti-inflammatory enhanced mitochondria, the fluorescence of JC-1 monomers increased and the fluorescence of JC-1 aggregates decreased. The fluorescence images were semi-quantitated using ImageJ, and the ratio of the fluorescence intensity of JC-1 aggregates to the fluorescence intensity of JC-1 monomers was used as the ordinate of the statistical graph. Fig.17 It can be seen that the mitochondrial membrane potential of the MITO group after mitochondrial treatment and the NEM-MITO group after anti-inflammatory enhanced mitochondria treatment were higher than those of the Model group (P < 0.05). By comparing the improvement of mitochondrial membrane potential by ordinary mitochondria and anti-inflammatory enhanced mitochondria, it was found that the repair ability of anti-inflammatory enhanced mitochondria was stronger than that of ordinary mitochondria (P < 0.01).

[0056] The same modeling and treatment methods were used to detect the changes in mitochondrial ATP in each group. The PLU value of each group was detected by chemiluminescence in a multifunctional microplate reader. The experimental results showed that the mitochondrial ATP content of Beas-2B cells treated with the supernatant of stimulated RAW264.7 cells was lower than that of unstimulated Beas-2B cells (P < 0.01). However, after treatment with ordinary mitochondria and anti-inflammatory enhanced mitochondria, the release of mitochondrial ATP in damaged Beas-2B cells was increased (P < 0.05). Compared with the repair ability of ordinary mitochondria, anti-inflammatory enhanced mitochondria have a stronger effect on improving damaged Beas-2B cells.

[0057] To further evaluate the repair of Beas-2B cells after injury, the release of ROS in each group was detected. The reactive oxygen species detection kit was used to measure the reactive oxygen species content of Beas-2B cells in the Control group, Model group, MITO group, and NEM-MITO group after stimulation. Fig. 22 (B) It can be seen that the reactive oxygen content in the Model group that was not treated with ordinary mitochondria and anti-inflammatory enhanced mitochondria was the highest, while after being treated with ordinary mitochondria and anti-inflammatory enhanced mitochondria, the reactive oxygen content had a certain downward trend, among which the downward trend in the anti-inflammatory enhanced mitochondria group was more obvious (P < 0.05).

[0058] The function of Beas-2B cells was detected by Elisa to detect AAT and by WB to determine the expression of ZO-1 and HO-1. Fig.23 (A) It can be found that when the supernatant of RAW264.7 cells induced by LPS was added to Beas-2B, the expression of AAT in the Model group was significantly increased compared with the Control group (P < 0.01), while the expression of AAT in the MITO group and NEM-MITO group with the addition of ordinary mitochondria and anti-inflammatory enhanced mitochondria was significantly decreased (P < 0.05). In order to further evaluate the changes in the function of Beas-2B cells, WB was used to detect the expression of ZO-1 and HO-1. Similarly, the Control group, Model group, MITO group, and NEM-MITO group were set. After modeling and drug treatment, the total cell protein of each group of cells was extracted, and the changes were evaluated by WB (Western Blot) method. All the results obtained were semi-quantitated using ImageJ, as shown in the following figure. Fig.23 As shown in (B) and (D), it was found that the ZO-1 and HO-1 of damaged Beas-2B in the Model group were downregulated (P < 0.05). The expression levels of ZO-1 and HO-1 proteins in the MITO group and NEM-MITO group, which were incubated with ordinary mitochondria and anti-inflammatory enhanced mitochondria, were significantly upregulated (P < 0.05). At the same time, the increase in protein levels in the MITO group and the NEM-MITO group was compared, and it was found that the expression levels of ZO-1 and HO-1 in the NEM-MITO group were higher than those in the MITO group. From the above results, it can be found that both ordinary mitochondria and anti-inflammatory enhanced mitochondria can improve the cellular function of Beas-2B cells, and the improvement ability of anti-inflammatory enhanced mitochondria is stronger than that of the ordinary mitochondria group.

Claims

1. Application of anti-inflammatory enhanced mitochondria in the preparation of drugs for treating sepsis, wherein the anti-inflammatory enhanced mitochondria are formed by binding an exogenous cell membrane to the outer membrane of an exogenous mitochondria.

2. The use according to claim 1, It is characterized in that Used for preparing medicines for treating sepsis and related complications.

3. The use according to claim 2, It is characterized in that Sepsis complications include at least one of septic shock, acute lung injury, and acute respiratory distress syndrome.

4. The use according to claim 1, It is characterized in that Anti-inflammatory enhanced mitochondria include at least one of features (A1) to (A2): (A1) the exogenous cell membrane is extracted from at least one of neutrophils, monocytes, lymphocytes, and tumor cells; (A2) The exogenous mitochondria are separated from cells or body tissues, and the body tissues include at least one of myocardial tissue, liver tissue, brain tissue, muscle tissue, blood, and tissue fluid.

5. The use according to any one of claims 1 to 4, It is characterized in that The drug has at least one of the effects (B1) to (B8): (B1) Alveolar septa are reduced; (B2) The number of inflammatory cells decreased; (B3) reducing serum inflammatory factors, including at least one of TNF-α, IL-6, and IL-1β; (B4) reducing liver function index values ​​and kidney function index values; (B5) Increase PaCO 2 level; (B6) Reduce the recruitment of neutrophils and inhibit the inflammatory infiltration of lung tissue; (B7) increased the expression levels of ZO-1 and HO-1 proteins; (B8) The content of active oxygen decreased.

6. The use according to any one of claims 1 to 4, It is characterized in that The medicine comprises an active ingredient and pharmaceutically acceptable excipients, wherein the active ingredient is anti-inflammatory enhanced mitochondria.

7. The use according to claim 6, It is characterized in that Pharmaceutically acceptable excipients include at least one of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and release retardants.

8. The use according to claim 7, It is characterized in that The dosage form of the drug includes at least one of oral liquid, powder, tablet, capsule, granule, decoction, pill, spray, inhalant, atomizer and injection.

9. The use according to claim 7 or 8, It is characterized in that The drug is used in combination with other anti-cancer drugs.

Citation Information

Patent Citations

  • Engineered mitochondria and preparation method thereof

    CN113122497A